Genexine Stock Price To Sales
Genexine fundamentals help investors to digest information that contributes to Genexine's financial success or failures. It also enables traders to predict the movement of Genexine Stock. The fundamental analysis module provides a way to measure Genexine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genexine stock.
Genexine |
Genexine Company Price To Sales Analysis
Genexine's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Genexine Price To Sales | 10.84 X |
Most of Genexine's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genexine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Genexine has a Price To Sales of 10.8429 times. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The price to sales for all Republic of Korea stocks is notably lower than that of the firm.
Genexine Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genexine's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genexine could also be used in its relative valuation, which is a method of valuing Genexine by comparing valuation metrics of similar companies.Genexine is currently under evaluation in price to sales category among its peers.
Genexine Fundamentals
| Return On Equity | -10.06 | |||
| Return On Asset | -0.0172 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | (0.41) % | |||
| Current Valuation | 2.14 T | |||
| Shares Outstanding | 20.55 M | |||
| Shares Owned By Insiders | 21.02 % | |||
| Shares Owned By Institutions | 7.17 % | |||
| Price To Sales | 10.84 X | |||
| Revenue | 36.83 B | |||
| Gross Profit | 9.76 B | |||
| EBITDA | (14.76 B) | |||
| Net Income | (48.56 B) | |||
| Cash And Equivalents | 27.8 B | |||
| Cash Per Share | 687.14 X | |||
| Total Debt | 40.79 B | |||
| Debt To Equity | 31.90 % | |||
| Current Ratio | 2.26 X | |||
| Book Value Per Share | 3,270 X | |||
| Cash Flow From Operations | (12.75 B) | |||
| Earnings Per Share | (1,283) X | |||
| Target Price | 121750.0 | |||
| Number Of Employees | 123 | |||
| Beta | 0.88 | |||
| Market Capitalization | 318.55 B | |||
| Total Asset | 636.86 B | |||
| Retained Earnings | (28.44 B) | |||
| Working Capital | 6.5 B | |||
| Current Asset | 11.66 B | |||
| Current Liabilities | 5.16 B | |||
| Z Score | 4.2 | |||
| Net Asset | 636.86 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Genexine Stock
Genexine financial ratios help investors to determine whether Genexine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genexine with respect to the benefits of owning Genexine security.